sphingosine kinase inhibitor During gastrulation the tempora

During gastrulation, the temporal and spatial determination of cell fates in different PS regions towards specific developmental lineages depends on the signalling cues in the surrounding environment. Members of the Transforming Growth Factor Beta (TGFβ) family (including BMP4 and Nodal) (Hogan, 1996; Conlon et al., 1994) and Wnt family members (Yamaguchi, 2001) play an essential role. Moreover, germ layer formation is a dynamic process that is tightly regulated by the coordinated activation and inhibition of BMP4, Activin/Nodal and Wnt signalling pathways (Gadue et al., 2005). The BMP4, Activin/Nodal and Wnt signalling pathways are required in establishing the cardiovascular system. Mouse and human PSCs represent distinct development stages, although the signalling pathways regulating human PSC differentiation are comparable to pathways controlling differentiation in mice. Knowledge, obtained from mouse embryonic development studies, has been translated to in vitro differentiation of human PSCs to improve their differentiation efficiency towards CMs (Sumi et al., 2008). The Wnt/β-catenin pathway has a stage-specific biphasic role in cardiomyogenesis. It is required for mesoderm induction, whereas inhibition occurs during the specification of the cardiac progenitor phase (Naito et al., 2006). Stimulating mouse and human PSCs with BMP4 alone or in combination with Activin/Nodal induces BRACHYURY and MIXL1 expression and the subsequent formation of KDR+ and PDGFR+ cardiac mesoderm (Laflamme et al., 2007; Kattman et al., 2011). The heart originates from the lateral plate mesoderm and develops in two distinct cardiomyogenesis waves from the primary (PHF) and secondary heart field (SHF). Both heart fields express KDR and the transcription factor NKX2.5, whereas the SHF is marked selectively by the transcription factor ISL1. These markers are useful to identify cardiac progenitor sphingosine kinase inhibitor (CPCs) from PSCs. Finally, the PHF gives rise to the left ventricle and both atria, while the SHF develops into the right ventricle and outflow tract (Wu et al., 2006).
Candidate Stem Cell Sources in Heart Regeneration Adult stem cells have cardiogenic differentiation capacity, and therefore present cardiac regenerative research focuses on developing stem cell sources to repair injured heart muscles. Several preclinical and clinical studies have been conducted, providing the pros and cons of various adult stem cell types for therapeutic approaches, including skeletal myoblasts, bone marrow-derived mononuclear cells (BMMNCs), mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs) and CPCs (Fig. 2). However, the ideal stem cell has not yet emerged and a limited number of studies have compared different stem cell types (Wollert and Drexler, 2005). Until now, all of these cell types have been thoroughly tested in clinical trials in the heart, except human ESCs and iPSCs.
Current Obstacles Towards Successful Therapeutic Applications For optimal potential applications of human ESCs and iPSCs in cardiovascular medicine, it is crucial to transplant highly pure human PSC-CM populations, lacking undifferentiated PSCs. This circumvents the PSC tumorigenicity and guarantees seamless integration of transplanted cells for the uninterrupted cardiac function. It is also mandatory to recapitulate the molecular, ultrastructural and electrophysiological characteristics of these PSC-CMs in respect to CMs exhibiting an adult phenotype (Table 1).
Novel Strategies for Stem Cell-Based Therapies Since the aforementioned obstacles are not yet completely overcome, the development of novel strategies for stem cell therapies in cardiac regeneration purposes remains the main focus. A successful stem cell therapy for cardiac diseases depends on cell delivery routes. Derivatives of PSCs can be systemically (intravenously or intracoronary) or locally (intramyocardial injection) administered. Intravenous cell delivery is particularly appealing because of the ease of administration. However, the major problem is the entrapment of the delivered cells in the pulmonary microcirculation. Intravenous cell injections require appropriate homing to the site of heart damage (Garbern and Lee, 2013). In 2003, a pioneer study, in which radioactively labelled EPCs were intravenously delivered into a rat MI model, showed a small portion of radioactivity (about 2%) in the heart after 24–96h (Aicher et al., 2003). Afterwards, these results have been confirmed with the use of other cells (Brenner et al., 2004; Nagaya et al., 2004). Intracoronary and intramyocardial routes are relatively more complex compared to intravenous injections. The most common delivery route for cell therapy after acute MI is the intracoronary route (Table 2). Main advantages include selective administration in the infarcted region and better uniform cell distribution in the target region. Intramyocardial injections have been shown to be superior to intravenous and intracoronary injections regarding cell retention. There is no need for homing signals because cells are administered directly in the myocardium. Both delivery routes have their limitations. The intracoronary injection demands a transient ischemic period, detrimental for the heart, to get the optimal distribution of the injected cells. While in an acute MI, the intramyocardial injection could increase the risk for perforation due to ischemia and necrosis (Hou et al., 2005). A comparative study of these three delivery routes in a porcine MI model demonstrated that the engraftment of the transplanted cells within the infarct zone 14days after delivery was significantly higher after intracoronary and intramyocardial injections than intravenous administration, respectively 106,000±43,000 and 51,000±24,000cells/g in respect to the absence of MSCs in the infarct zone after intravenous injection (Freyman et al., 2006). In the near future, the advance of transplantation techniques might provide a more efficient method for injected stem cells to retain and survive in the damaged heart.